Article Dans Une Revue ESMO Open Année : 2024

Lurbinectedin in extensive-stage small-cell lung cancer: a brief report of the IFCT-2105 LURBICLIN study

E. Pichon
  • Fonction : Auteur
A. Tiotiu
  • Fonction : Auteur
A. Madroszyk
A. Canellas
L. Belmont
B. Godbert
  • Fonction : Auteur
C. Audigier-Valette
  • Fonction : Auteur
C. Lebreton
  • Fonction : Auteur
F. Morin

Résumé

Background: Small-cell lung cancer (SCLC) is a highly aggressive type of lung cancer. Lurbinectedin is recommended as second-/third-line treatment for advanced, previously treated SCLC. Materials and methods: LURBICLIN is a nationwide, non-interventional, retrospective chart review study, based on the cohort of consecutive patients enrolled in the named patient use for lurbinectedin in France. Results: A total of 312 patients were included. Lurbinectedin was delivered as second-line therapy in 138 (44%) patients. Grade 3-4 treatment-related adverse events were observed in 28 (9%) and 15 (5%) patients, respectively. Objective response rate (ORR) to lurbinectedin was 22% in the intention-to-treat population. After a median follow-up of 20.8 months, median progression-free survival (PFS) was 1.9 months [95% confidence interval (CI) 1.8-2.0 months]. At multivariate analysis, chemotherapy-free interval (CTFI) ≥ 90 days was an independent predictor of higher PFS [hazard ratio (HR) = 0.64, 95% CI 0.50-0.84, P < 0.0001]. The median overall survival (OS) was 4.7 months (95% CI 4.0-5.4 months). At multivariate analysis, performance status < 2 and CTFI ≥ 90 days were independent predictors of higher OS (HR = 0.71, 95% CI 0.53-0.95, P = 0.03; and HR = 0.58, 95% CI 0.44-0.76, P < 0.0001, respectively). Overall, 147 (47%) patients had initiated subsequent systemic treatments. Conclusions: LURBICLIN confirms the activity of lurbinectedin in patients with SCLC with a manageable safety profile. Lurbinectedin monotherapy provides an alternative option for SCLC patients.
Fichier principal
Vignette du fichier
1-s2.0-S2059702924017381-main.pdf (388.59 Ko) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte
licence

Dates et versions

hal-04831085 , version 1 (16-01-2025)

Licence

Identifiants

Citer

Nicolas Girard, F. Guisier, A. Swalduz, S. van Hulst, E. Pichon, et al.. Lurbinectedin in extensive-stage small-cell lung cancer: a brief report of the IFCT-2105 LURBICLIN study. ESMO Open, 2024, 9 (12), ⟨10.1016/j.esmoop.2024.103968⟩. ⟨hal-04831085⟩
9 Consultations
0 Téléchargements

Altmetric

Partager

More